RxDoctor Payments DataLook up a doctor →

Eric Lawitz, MD

Gastroenterology · San Antonio, TXNPI 1578661716

Payments from drug & device makers

$59,485,366in general payments, 2019–2025

Across 4,327 payments — averaging $13,747 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$10.9M
  • Boehringer Ingelheim$6.7M
  • Astrazeneca UK Limited$5.1M
  • Gilead$3.3M
  • Eli Lilly$3.2M
  • Boehringer Ingelheim International GmbH$3.2M
  • plus $27.1M from 54 others
$48,845in research payments, 2019–2025

Across 69 payments — averaging $707.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$29K
  • Eli Lilly$13K
  • Novartis$2K
  • Corcept Therapeutics$2K
  • Regeneron$2K
  • Gilead$452
  • plus $121 from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.61$10,853,269
Boehringer Ingelheim70$6,731,551
Astrazeneca UK Limited27$5,088,576
Gilead445$3,252,196
Eli Lilly46$3,238,157
Boehringer Ingelheim International GmbH932$3,183,132
Novartis29$3,142,319
GSK98$2,526,668
Amgen(2 entities)16$2,428,569
Intercept Pharmaceuticals, Inc.306$2,261,559
CTI Biopharma Corp.48$1,617,630
Takeda Pharmaceuticals U.S.A., Inc.124$1,449,086
Bristol Myers Squibb17$1,387,367
Deciphera Pharmaceuticals Inc.17$1,327,995
Genentech, Inc.50$866,842
Vertex4$808,525
Janssen Research & Development, LLC19$789,695
Ipsen Bioscience Inc.108$775,514
Bausch Health US, LLC9$773,501
AbbVie(2 entities)123$705,643
AstraZeneca12$615,167
Incyte Corporation25$611,446
Astellas Pharma Inc28$488,811
F. Hoffmann-la Roche AG32$443,194
Provepharm Inc.4$425,339
Novo Nordisk AS625$402,839
X4 Pharmaceuticals, Inc.77$328,217
PTC Therapeutics, Inc.20$327,376
Kadmon Corporation LLC2$286,813
Regeneron316$245,572
Sobi, Inc5$235,459
Mallinckrodt Hospital Products Inc.13$172,972
Novo Nordisk66$150,677
Sunovion Pharmaceuticals Inc.225$139,263
Merck32$130,592
Braintree Laboratories, Inc.8$126,216
Ipsen Pharma SAS44$122,589
Exelixis Inc.11$120,079
Biocryst Pharmaceuticals, Inc.5$112,210
Madrigal Pharmaceuticals35$91,783
Intercept Pharma Europe Ltd.7$91,216
Insmed, Inc.10$71,757
Lexicon Pharmaceuticals, Inc.6$71,478
Grifols Shared Services North America, Inc.6$68,617
Alnylam Pharmaceuticals Inc.30$62,000
Astrazeneca AB1$55,200
Sanofi US Services Inc.4$51,493
Boehringer Ingelheim RCV GmbH & Co KG35$38,903
Akebia Therapeutics Inc7$28,461
H. Lundbeck A S2$28,100
Ipsen Biopharmaceuticals, Inc15$27,251
Mallinckrodt Enterprises LLC3$25,418
Xeris Pharmaceuticals, Inc.4$24,614
Sumitomo Pharma America, Inc.5$16,511
Corcept Therapeutics6$8,842
Boehringer Ingelheim Pharma GmbH & Co.kg28$7,404
Siemens Medical Solutions USA, Inc.7$7,177
Dova Pharmaceuticals5$4,218
Mirati Therapeutics, Inc.1$3,500
Zogenix Inc.3$2,785

How this compares

$59,485,366 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Medicare billing

Part B allowed, 2024
$70,531
Medicare patients
473
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in San Antonio

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →